3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Small Cell Lung Carcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Pemetrexed
3
Carboplatin
3
durvalumab
2
Cisplatin
2
tremelimumab
1
repotrectinib
1
pralsetinib
1
osimertinib
1
brigatinib
1
atezolizumab
1
Surgical Procedures, Operative
1
Paclitaxel
1
Mitomycin
1
Gemcitabine
1
Crizotinib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Carcinoma
×
durvalumab
×
Clear all
NCT03703297
2025-11-21
ADRIATIC
AstraZeneca
Phase 3
Active not recruiting
730 enrolled
19 charts
1 FDA
NCT03800134
2025-06-11
AEGEAN
AstraZeneca
Phase 3
Active not recruiting
825 enrolled
1 FDA